WHO ICTRP trial
Nox 1 and 4 inhibition in type 1 diabetic kidney disease
ACTRN12617001187336 · Australian New Zealand Clinical Trials Registry (ANZCTR) · Not Recruiting
Key facts
| Trial ID | ACTRN12617001187336 |
|---|---|
| Public title | Nox 1 and 4 inhibition in type 1 diabetic kidney disease |
| Scientific title | A physician-initiated double-blind, randomised, placebo-controlled , phase 2 study evaluating the efficacy and safety of inhibition of NADPH Oxidase with the first-in-class Nox-1/4 inhibitor, GKT137831, in adults with type 1 diabetes and persistently elevated urinary albumin excretion. |
| Primary sponsor | Baker Heart and Diabetes Institute |
| Registry | Australian New Zealand Clinical Trials Registry (ANZCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase 2 |
| Countries | Australia;New Zealand |
| Conditions | diabetic kidney disease;type 1 diabetes; diabetic kidney disease type 1 diabetes;Metabolic and Endocrine - Diabetes;Renal and Urogenital - Kidney disease |
| Interventions | GKT137831, 400 mg twice a day taken as oral capsules for 48 weeks, added to standard of care treatment for albuminuric diabetic kidney disease. Adherence to the intervention will be monitored by drug capsule return. |
| Registration date | Aug 14, 2017 |
| Target size | 92 |
| Secondary IDs | Protocol number: T1DGKT137831;GSN000241 |
| Registry page | anzctr.org.au |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: